Effect of modified Xiaochaihu decoction‑containing serum on HepG2.2.15 cells via the JAK2/STAT3 signaling pathway

Chen,Shaofang; Wang,Zhanglin; Wan,Shichuan; Huang, Hai; Liang,Huiqing

doi:10.3892/mmr.2017.7561

Effect of modified Xiaochaihu decoction‑containing serum on HepG2.2.15 cells via the JAK2/STAT3 signaling pathway

Authors:
- Shaofang Chen
- Zhanglin Wang
- Shichuan Wan
- Hai Huang
- Huiqing Liang
View Affiliations

Affiliations: College of Chinese Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China
Published online on: September 20, 2017 https://doi.org/10.3892/mmr.2017.7561
Pages: 7416-7422
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the possible mechanisms underlying the effect of modified Xiaochaihu decoction (mXCHD) in the treatment of chronic hepatitis B (CHB). Patients with CHB, in addition to liver stagnation and spleen deficiency syndrome were randomly assigned to receive either Chinese (mXCHD) or western (entecavir) treatment, with 30 cases in each group. Serum was collected following treatment with mXCHD or entecavir for 7 days. A healthy group of 30 individuals was also included. HepG2.2.15 cells were cultured in vitro and randomly divided into four groups: Healthy; entecavir‑treated; 10% mXCHD‑treated; and 20% mXCHD‑treated. The HepG2.2.15 cells in the four groups were treated with either serum from the healthy volunteers, entecavir‑containing serum, or mXCHD‑containing serum at different concentrations (10 or 20%, respectively). Following treatment with the corresponding serum, cell proliferation was examined using an MTT assay, and the expression of hepatitis B surface antigen (HBsAg) in the cell supernatant was detected using an enzyme‑linked immunosorbent assay. The mRNA and protein expression levels of Janus kinase (JAK)2 and signal transducer and activator of transcription (STAT)3 were measured using reverse transcription‑quantitative polymerase chain reaction and western blot analyses, respectively. The results indicated that the most effective treatment for the promotion of HepG2.2.15 cell proliferation was a 20% concentration of mXCHD serum. The expression of HBsAg was significantly decreased in the groups treated with 10 and 20% mXCHD 48 h following intervention (P<0.01). The mRNA and protein expression levels of STAT3 in the 20% mXCHD serum group were significantly increased, compared with those in the healthy group (P<0.01 and P<0.05, respectively), whereas no significant difference was observed in the expression of JAK2 among the four groups. These results indicated that mXCHD suppressed the hepatitis B virus, and treatment of the cells with mXCHD‑containing serum promoted HepG2.2.15 cell proliferation via modulating the expression of STAT3, which may contribute to the clinical efficacy of mXCHD against CHB.

View Figures

View References

1	World Health Organization: Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva: WHO. 1–11. 2015.
2	Varbobitis I and Papatheodoridis GV: The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy. Clin Mol Hepatol. 22:319–326. 2016. View Article : Google Scholar : PubMed/NCBI
3	Intaraprasong P, Siramolpiwat S and Vilaichone RK: Advances in management of hepatocellular carcinoma. Asian Pac J Cancer Prev. 17:3697–3703. 2016.PubMed/NCBI
4	Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH, et al: Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2012 update. Hepatol Int. 6:531–561. 2012. View Article : Google Scholar : PubMed/NCBI
5	Tsai MC, Chen CH, Hu TH, Lu SN, Lee CM, Wang JH and Hung CH: Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos (t)ide analogs. J Formos Med Assoc. 115:883–889. 2016.PubMed/NCBI
6	Qin XK, Li P, Han M and Liu JP: Xiaochaihu Tang for treatment of chronic hepatitis B: A systematic review of randomized trials. Zhong Xi Yi Jie He Xue Bao. 8:312–320. 2010.(In Chinese). View Article : Google Scholar : PubMed/NCBI
7	Zhao F, An LF, Ma YQ and Yang KF: Efficacy of singly Chinese herbal drugs for hepatitis B virus in vitro and in vivo: A systematic review. Chinese Traditional Patent Medicine (Chin). 37:2282–2285. 2015.(In Chinese).
8	Bai Y, Xia FN, Zhou SH, Yu KH and Liu JH: Regulating effect of traditional Chinese medicines for Enh II and core promoter of hepatitis B virus. Lishizhen Medicine and Materia medica Research (Chin). 26:1534–1536. 2015.(In Chinese).
9	Wang Y: Effect of Xiaochaihu decoction combined with western medicine on liver function and HBV DNA copies in patient with chronic hepatitis B. Journal of New Chinese Medicine (Chin). 48:74–76. 2016.(In Chinese).
10	Chen DD and Gong ZJ: The clinical study of Xiaochaihu decoction in treatment of chronic hepatitis B patients with liver fibrosis. Modern Journal of Integrated Traditional Chinese and Western Medicine (Chin). 20:3928–3929. 2011.(In Chinese).
11	Zhao CH: Clinical observation on 40 cases of HBeAg-positive chronic hepatitis B treated with modified Xiaochaihu decoction combined with adefovior. Henan Traditional Chinese Medicine (Chin). 34:1924–1925. 2014.(In Chinese).
12	Wang MH, Zheng DR and Cheng Q: Clinical Research of modified Xiaochaihu decoction combined with adefovior in treatment of chronic hepatitis B patients. Journal of Community Medicine (Chin). 12:30–31. 2014.(In Chinese).
13	Xiao-qiu Liu, Xiao-jian Hu, Hong-Xing Xu and Xiao-Ying Zeng: Xiaochaihu decoction attenuates the vicious circle between the oxidative stress and the ALP inactivation through LPS-catecholamines interactions in gut, liver and brain during CCI₄+ethanol-induced mouse HCC. BMC Complement Altern Med. 13:3752013. View Article : Google Scholar : PubMed/NCBI
14	Liu XB, Wang J, Zhang QQ, Liu T, Dang TM and Cao YM: The protective effect of XD in ConA-induced liver injury. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 26:1193–1194. 2010.(In Chinese). PubMed/NCBI
15	Li J, Xie M and Gan Y: Effect of Xiaochaihu decoction and different herbal formulation of component on inhibiting H22 liver cancer in mice and enhancing immune function. Zhongguo Zhong Yao Za Zhi. 33:1039–1044. 2008.(In Chinese). PubMed/NCBI
16	Sun MY, Xie M, Zhang N, Yi L and Wang S: Effect of xiaochaihu decoction and different herbal formulations of its components on cytokines of carrageenan induced pleuritis in rats. Zhongguo Zhong Xi Yi Jie He Za Zhi (Chin). 24:628–631. 2004.(In Chinese).
17	Liu Z, Xiong M and Zhang H: Experimental study on inhibitory effect of xiaochaihu decoction on duck hepatitis B virus. Zhongguo Zhong Xi Yi Jie He Za Zhi. 20:853–855. 2000.(In Chinese). PubMed/NCBI
18	Sun XH, Wang ZL and Liu ZJ: Effect of modified Xiaochaihu decoction on HBV-DNA levels in sera and liver tissue in transgenic mice. Chinese Journal of Integrated Traditional and Western Medicine on Digestion (Chin). 19:91–93. 2011.(In Chinese).
19	Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association: The guideline of prevention and treatment for chronic hepatis B (2010 version). Zhonghua Gan Zang Bing Za Zhi. 19:13–24. 2011.(In Chinese). PubMed/NCBI
20	The Internal Medicine Department Committee of Liver Disease in Chinese Traditional Chinese Medicine Association: TCM syndrome differentiation standards of Viral hepatitis (Trial). Journal of Traditional Chinese Medicine (Chin). 5:39–40. 1992.(In Chinese).
21	World Medical Association: World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA. 310:2191–2194. 2013. View Article : Google Scholar : PubMed/NCBI
22	Chinese Pharmacopoeia Commission: Pharmacopoeia of the People's Republic of China (volume 4, 2015 version). Beijing: China Medical Science Press; pp. 7–151. 2015, (In Chinese).
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Boucle S, Bassit L, Ehteshami M and Schinazi RF: Toward elimination of Hepatitis B virus using novel drugs, approaches and combined modalities. Clin Liver Dis. 20:737–749. 2016. View Article : Google Scholar : PubMed/NCBI
25	Jeng WJ, Chen YC, Sheen IS, Lin CL, Hu TH, Chien RN and Liaw YF: Clinical relapse after cessation of tenofovir therapy in Hepatitis B e antigen-negative patients. Clin Gastroenterol Hepatol. 14:1813–1820. 2016. View Article : Google Scholar : PubMed/NCBI
26	Xia J, Inagaki Y, Song P, Sawakami T, Kokudo N, Hasegawa K, Sakamoto Y and Tang W: Advance in studies on traditional Chinese medicines to treat infection with the hepatitis B virus and hepatitis C virus. Biosci Trends. 10:327–336. 2016. View Article : Google Scholar : PubMed/NCBI
27	Xiong MQ, Wang QG, Guan QZ, et al: Science of Exogenous Febrile Diseases. Beijing: China Press of Traditional Chinese Medicine; pp. 263–272. 2003, (In Chinese).
28	Gu JP, Wang CL, Zhang FF, et al: Pharmacology of Traditional Chinese Medicine. Shanghai: East China University of Science and Technology Press; pp. 110–229. 2015, (In Chinese).
29	Li L, Lei QS, Zhang SJ, Kong LN and Qin B: Suppression of USP18 potentiates the anti-HBV activity of interferon Alpha in HepG2.2.15 cells via JAK/STAT signaling. PLoS One. 11:e01564962016. View Article : Google Scholar : PubMed/NCBI
30	Zhu X, Xie C, Li YM, Huang ZL, Zhao QY, Hu ZX, Wang PP, Gu YR, Gao ZL and Peng L: TMEM2 inhibits hepatitis B virus infection in HepG2 and HepG2.2.15 cells by activating the JAK-STAT signaling pathway. Cell Death Dis. 7:e22392016. View Article : Google Scholar : PubMed/NCBI
31	Guan SH, Yang K, Lu MJ, Lu YP and Yang DL: The influence of HBV and its antigens on the expressions of JAK-STAT signal transduction pathway molecules and antiviral proteins of IFN alpha. Zhonghua Gan Zang Bing Za Zhi. 19:440–444. 2011.(In Chinese). PubMed/NCBI
32	Bock CT, Toan NL, Koeberlein B, Song le H, Chin R, Zentgraf H, Kandolf R and Torresi J: Subcellular mislocalization of mutant hepatitis B X proteins contributes to modulation of STAT/SOCS signaling in hepatocellular carcinoma. Intervirology. 51:432–443. 2008. View Article : Google Scholar : PubMed/NCBI
33	Churin Y, Roderfeld M, Stiefel J, Würger T, Schröder D, Matono T, Mollenkopf HJ, Montalbano R, Pompaiah M, Reifenberg K, et al: Correction: Pathological impact of hepatitis B virus surface proteins on the liver is associated with the host genetic background. PLoS One. 10:e01273752015. View Article : Google Scholar : PubMed/NCBI
34	Li W, Liang X, Kellendonk C, Poli V and Taub R: STAT3 contributes to the mitogenic response of hepatocytes during liver regeneration. J Biol Chem. 277:28411–28417. 2002. View Article : Google Scholar : PubMed/NCBI
35	Schwabe RF, Bradham CA, Uehara T, Hatano E, Bennett BL, Schoonhoven R and Brenner DA: c-Jun-N-terminal kinase drives cyclin D1 expression and proliferation during liver regeneration. Hepatology. 37:824–832. 2003. View Article : Google Scholar : PubMed/NCBI
36	Chen XL, Meng Q and Liu KX: Role of STAT3 signaling pathway in repair of liver injury. World Chinese Journal of Digestology (Chin). 22:1051–1057. 2014.(In Chinese). View Article : Google Scholar